Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU slightly cuts estimates for vaccine deliveries this year

06/24/2021 | 11:48am EDT

BRUSSELS, June 24 (Reuters) - The European Commission estimates European Union countries will receive about 900 million doses of COVID-19 vaccines in the second half of the year, compared to nearly 1 billion shots it expected a month ago, an internal document showed.

The document, which the EU executive shared with EU leaders at a summit in Brussels on Thursday, also showed the EU is forecast to receive fewer doses in the first half of the year, compared to its own predictions in late May.

This is not expected to affect the EU's target of vaccinating 70% of its adult population in the summer, but it indicates that supply difficulties may still force changes in vaccine rollouts.

The document, seen by Reuters, showed the bloc forecast it would get about 500 million doses in the third quarter of the year, and another 400 million between October and December from four makers: Pfizer/BioNTech, Moderna, AstraZeneca and Johnson & Johnson.

In the first half of the year, the EU has received 424 million doses, the document said, showing deliveries expected until June 27. That has allowed it to vaccinate with at least one dose 220 million people, or 60% of the EU's adult population.

In another internal document, seen by Reuters and presented to EU leaders at the end of May, the EU Commission had estimated 980 million doses would have arrived in the second half of the year, of which 529 million in the third quarter.

It also had expected 519 million vaccines in the first six months of the year, nearly 100 million more than it has actually received so far.

The small drop in the third quarter is mostly caused by a reduction in supplies due from Johnson & Johnson, which has faced production problems.

The U.S. company is forecast to deliver only 7 million doses in July, the EU document shows, after it was expected to miss its supply target in the second quarter.

Pfizer, the EU's main supplier, is forecast to deliver slightly fewer vaccines in the last quarter of the year than the EU expected in May, the documents show.

(Reporting by Sabine Siebold and Francesco Guarascio, Editing by Gabriela Baczynska, Mark Heinrich and Giles Elgood)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.25% 8480 Delayed Quote.15.78%
MODERNA, INC. 7.84% 348.83 Delayed Quote.233.90%
PFIZER, INC. 0.51% 41.68 Delayed Quote.13.23%
All news about ASTRAZENECA PLC
09:06aDR Congo Faces Major Challenges in Covid-19 Vaccine Rollout
AQ
02:54aASTRAZENECA : scours supply chain for more vaccine doses for Thailand, SE Asia
RE
07/23PFIZER : Brazil reopens amid looming threat from delta variant
AQ
07/23Relaxed Border Restrictions For U.S. Travelers Coming August 9, 2021
AQ
07/23CORONAVIRUS – TUNISIA : Belgium sends emergency aid to Tunisia in the figh..
AQ
07/23ASTRAZENECA : Secures FDA Approval for Bydureon BCise Injectable Suspension for ..
MT
07/23AstraZeneca’s BYDUREON BCise Approves in the Us for the Treatment of Type 2 D..
CI
07/23AstraZeneca's Bydureon BCise Gets U.S. Approval For Type 2 Diabetes in Pediat..
DJ
07/23CORRECTION : AstraZeneca Says Data Shows One Dose of COVID-19 Jab 'Highly Effect..
MT
07/23ASTRAZENECA : Single-Dose COVID-19 Jab Shows Effect Against Beta, Gamma, Delta V..
MT
More news
Financials (USD)
Sales 2021 31 752 M - -
Net income 2021 4 669 M - -
Net Debt 2021 10 816 M - -
P/E ratio 2021 33,0x
Yield 2021 2,42%
Capitalization 181 B 181 B -
EV / Sales 2021 6,03x
EV / Sales 2022 5,25x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 116,57 $
Average target price 132,19 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC15.78%155 197
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246